Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Zivo Bioscience Inc. Warrants (ZIVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZIVOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.08% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.33M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.12 - 2.38 | Updated Date 05/26/2025 |
52 Weeks Range 0.12 - 2.38 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13411.4% |
Management Effectiveness
Return on Assets (TTM) -948.38% | Return on Equity (TTM) -3956.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1365620 |
Shares Outstanding - | Shares Floating 1365620 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Zivo Bioscience Inc. Warrants
Company Overview
History and Background
Zivo Bioscience, Inc. is a biotechnology company focused on developing proprietary algal strains for nutritional and pharmaceutical applications. While the exact founding date and early milestones of the warrants are difficult to pin down without more precise information, warrants are derivative securities that usually accompany an equity offering.
Core Business Areas
- Animal Feed Supplements: Developing algal-based supplements to improve animal health and nutrition. The warrants provide the right to purchase shares of Zivo common stock.
- Pharmaceutical Applications: Exploring the use of algal compounds for potential therapeutic applications in humans. The value of the warrants is derived from the underlying value of the Zivo Bioscience common stock.
Leadership and Structure
Zivo Bioscience has a management team and board of directors. The warrants themselves don't have a leadership team but are a financial instrument tied to the company's overall performance. As such, changes in management would impact the warrants.
Top Products and Market Share
Key Offerings
- Animal Feed Ingredient (Projected): Zivo is developing an algal-based animal feed ingredient, but its market share and revenue are currently minimal as the product is not yet commercially available. Competitors include established animal feed companies and suppliers of alternative protein sources. More information on product names are needed.
- Pharmaceuticals (Research Stage): Zivo's pharmaceutical research is in early stages, with no products currently on the market. Therefore, it has no market share or revenue. Competitors include pharmaceutical companies researching and developing therapies in similar areas. More information on specific drug names are needed.
Market Dynamics
Industry Overview
The animal feed and pharmaceutical industries are large and competitive. The animal feed industry is driven by the demand for efficient and sustainable animal nutrition, while the pharmaceutical industry is driven by the need for new and effective treatments for various diseases.
Positioning
Zivo aims to carve out a niche in both industries by leveraging its unique algal platform. The warrants' value is tied to Zivo's success in developing and commercializing these products, but that has not yet been achieved.
Total Addressable Market (TAM)
The TAM for animal feed supplements and pharmaceuticals is significant, totaling hundreds of billions of dollars. Zivo's positioning is as an innovator, aiming to capture a small but growing share of these markets with its algal-based products. It is positioned as a high-risk high-reward.
Upturn SWOT Analysis
Strengths
- Proprietary algal platform
- Potential for sustainable and scalable production
- Focus on animal and human health applications
- Warrants offer potential for leveraged gains if the company is successful
Weaknesses
- Early stage of development
- Limited commercial traction
- High R&D expenses
- Dependence on successful clinical trials and regulatory approvals
- Warrants are subject to price volatility
- Limited information on financial position
Opportunities
- Growing demand for sustainable animal feed
- Increasing interest in algal-based products
- Potential partnerships with established companies
- Expanding into new markets and applications
Threats
- Competition from established players
- Regulatory hurdles
- Technological risks
- Market acceptance challenges
- Economic downturns
- Dilution of shareholder value
Competitors and Market Share
Key Competitors
- DSM (DSM.AS)
- Cargill (Private)
- ADM (ADM)
Competitive Landscape
Zivo is a small player compared to established giants like DSM and Cargill. Its competitive advantage lies in its novel algal platform and potential for sustainable production. However, it faces significant challenges in scaling up production and competing on price.
Growth Trajectory and Initiatives
Historical Growth: Historical growth of the warrants is tied to the fluctuation of the underlying stock price of Zivo Bioscience. Any growth or decline would be representative of the underlying common stock.
Future Projections: Future projections for the warrants are dependent on the projections of the underlying common stock of Zivo Bioscience and any analyst estimates for Zivo Bioscience's underlying common stock
Recent Initiatives: Recent initiatives by Zivo Bioscience would directly impact the price and value of the warrants.
Summary
Zivo Bioscience is a high-risk, high-reward biotechnology company with a promising algal platform. The warrants offer the potential for leveraged gains but are highly speculative. The company needs to achieve commercial success to validate its technology and create value for warrant holders. Key areas to watch include R&D progress, partnerships, and regulatory approvals. There is very limited publicly accessible information on the stock and the financial viability of the stock is unclear.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and is subject to change. Investors should conduct their own due diligence before making any investment decisions. Market share estimates are based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zivo Bioscience Inc. Warrants
Exchange NASDAQ | Headquaters Troy, MI, United States | ||
IPO Launch date 2021-05-28 | President, CEO & Chairman of the Board Mr. John Bernard Payne | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zivobioscience.com |
Full time employees 7 | Website https://www.zivobioscience.com | ||
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.